Active substanceDipyridamoleDipyridamole Similar drugsTo uncover Dipyridamole pills inwards ATOLL, LLC Russia Dipyridamole suspension inwards Rosemont Pharmaceuticals Ltd. United Kingdom Dipyridamole pills inwards VERTEKS, AO Russia Dipyridamole-FPO® pills inwards OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC Russia Curantil® 25 pills inwards BERLIN-PHARMA, CJSC Russia Kurantil® N 25 pills inwards BERLIN-PHARMA, CJSC Russia Curantil® N 75 pills inwards BERLIN-PHARMA, CJSC Russia Sanomil-Sanovel pills inwards Sanovel Pharmaco-industrial trading company Turkey Dosage form: & nbspFilm-coated tablets. Composition:each film-coated tablet contains: active substance: dipyridamole 75 mg;Excipients: corn starch, lactose monohydrate, gelatin, silicon dioxide colloid, talc, magnesium stearate;film sheath: (carmellose sodium, maltodextrin, dextrose monohydrate, lecithin, sodium citrate dihydrate), opacrame red (carmellose sodium, dextrose monohydrate, maltodextrin, titanium dioxide, lecithin, sunscreen dye yellow, sodium citrate dihydrate, dye crimson [Ponso 4R]), . Description:Round biconvex tablets covered with a film coating of red color, on a broken yellow color. Pharmacotherapeutic group:Vasodilating agent. ATX: & nbspB.01.A.C.07 Dipyridamole Pharmacodynamics:Dipyridamole expands coronary vessels (mainly arterioles) and causes a significant increase in the volume flow rate. Increases the oxygen content in the venous blood of the coronary sinus and its absorption by the myocardium. Promotes the development of collateral coronary circulation, reduces the overall peripheral resistance of blood vessels, improves microcirculation, has an angioprotective effect. These effects are due to the increased activity of endogenous adenosine due to a decrease in its capture by tissues and destruction (adenosine affects the smooth musculature of the vessels and prevents the release of norepinephrine).It is an antagonist of the endogenous adenosine diphosphate (ADP) aggregate, inhibits phosphodiesterase, while the release of platelet aggregation activators, thromboxane, ADP, serotonin, etc., decreases, increases the synthesis of prostacyclin PgI2 endothelium of the vascular tissue, which hinders the aggregation of platelets.Reduces adhezivnost platelets, prevents the formation of clots in the blood vessels and reduce blood flow in the source of ischemia. Antiaggregant effect occurs at a plasma concentration of 0.1 μg / ml. Dose-dependent extends the abnormally shortened lifetime of thrombocytes.Expands coronary arteries, especially unchanged, causes the phenomenon of stealing. It is an interferon inducer, has a modulating effect on the functional activity of the interferon system, increases the decreased production of interferon alpha and gamma-leukocytes in vitro. Increases nonspecific antiviral resistance to viral infections.Normalizes venous outflow, reduces the incidence of deep vein thrombosis in the postoperative period. Improves microcirculation in the retina of the eye, renal glomeruli. Reduces the tone of the cerebral vessels, it is effective for dynamic disorders of cerebral circulation. Pharmacokinetics:When ingested quickly absorbed in the stomach (most) and the small intestine. Bioavailability is 37-66%. After oral administration, the maximum concentration of dipyridamole in plasma is reached within 40-60 minutes. It binds to plasma proteins by 80-95%.Quickly penetrates into the tissue. It accumulates in large quantities in the heart and red blood cells. The half-life is 20-30 minutes in the first phase, in the second phase - about 10 hours. It is metabolized in the liver with the formation of monoglyucuronide, which is excreted in the bile (20% of the drug is included in the enterohepatic circulation). Possible cumulation (mainly in patients with impaired liver function). Indications:- Thrombosis and thromboembolism (prophylaxis of arterial and venous thrombosis, including after the operation of prosthetic valve of the heart);- Prevention of occlusion of stents and coronary artery bypass grafts (in combination with ASA);- Treatment and prevention of cerebral circulation disorders according to the ischemic type; encephalopathy;- Disturbances of microcirculation of any genesis (as part of complex therapy). Contraindications:Hypersensitivity to the drug components, acute myocardial infarction, widespread sclerosing arteriosclerosis of the coronary arteries, unstable angina, hypertrophic obstructive cardiomyopathy, decompensated chronic heart failure, arterial hypotension, severe arterial hypertension,severe disorders of the heart rhythm, hemorrhagic diathesis, peptic ulcer and duodenal ulcer (tendency to bleeding), chronic obstructive pulmonary disease, renal failure, hepatic insufficiency, children's age (under 18 years). Pregnancy and lactation:Dipyridamole can be used during pregnancy, if only the expected therapeutic effect justifies the potential risk to the fetus, which should especially be taken into account in the first trimester of pregnancy.Dipiridamole penetrates into the mother's milk, in connection with which dipyridamole can not be used during breastfeeding. (see Contraindications "children's age (under 18 years)) Dosing and Administration:Inside, on an empty stomach or 1 hour before a meal, washed down with a small amount of water or milk.For prevention and treatment of thromboembolic complications as monotherapy - 75 mg 3-6 times a day; a daily dose of 300-450 mg, if necessary - 600 mg; in combination with oral anticoagulants or with ASA - 75 mg 3 times a day.For the prevention of thromboembolic syndrome, stent thrombosis and aortocoronary shunts - on the first day of 50 mg together with ASA, then 100 mg,the frequency of reception is 4 times a day (cancels seven days after the onset, if the ASA continues to be taken at a dose of 325 mg / day) or 100 mg 4 times a day for 2 days before surgery and 100 mg 1 hour after surgery need in combination with warfarin).In case of coronary insufficiency, 25-50 mg 3 times a day; in severe cases at the beginning of treatment - 75 mg 3 times a day, then reduce the dose; daily dose of 150-200 mg. Side effects:From the cardiovascular system: palpitations, tachycardia, bradycardia, blood flushes to the face, coronary steal syndrome (with doses more than 225 mg / day), lowering blood pressure.From the digestive system: nausea, vomiting, diarrhea, epigastric pain.From the side of blood and hemostasis system: thrombocytopenia, changes in the functional properties of thrombocytes, bleeding, increased bleeding.Other: weakness, dizziness, a feeling of stuffiness in the ear, noise in the head, headache, facial flushing, arthritis, myalgia, rhinitis, allergic reactions. Overdose:When an overdose occurs, headache, gastrointestinal disorders, lowering blood pressure.With a decrease in blood pressure if necessary, short-term intake of vasopressor preparations is recommended.In patients with coronary heart disease, coronary vasodilation can lead to chest pain. Chest pain and bronchospasm are eliminated by immediate intravenous injection of aminophylline and nitroglycerin.In case of an overdose, general symptomatic treatment is performed. Interaction:The antiplatelet effect is increased with the use of indirect anticoagulants, acetylsalicylic acid, penicillin series antibiotics, cephalosporins, tetracyclines, chloramphenicol, nicotinic acid.The xanthine derivatives containing caffeine, weaken the antithrombotic effect. Weaken the effect of cholinesterase inhibitors.Antacids reduce the maximum concentration due to reduced absorption.Heparin, indirect anticoagulants, thrombolytics increase the risk of hemorrhagic complications. Special instructions:To reduce the dyspeptic phenomena are taken with milk. In the treatment should be avoided the use of coffee and tea, weakening the effect of dipyridamole.In the syndrome of coronary stealing to improve intracardiac blood flow, the appointment of aminophylline is indicated. Effect on the ability to drive transp. cf. and fur: Form release / dosage:Tablets coated with a film membrane 75 mg. Packaging:For 15 tablets in a blister of PVC-aluminum foil. For 6 blisters in a cardboard bundle together with instructions for use. Storage conditions:List B.In a dry place at a temperature of no higher than 25 ° C.Keep out of the reach of children. Shelf life:3 years. Do not use after the expiration date printed on the package. Terms of leave from pharmacies:On prescription Registration number:LSR-009538/09 Date of registration:25.11.2009 Expiration Date:Unlimited The owner of the registration certificate:Sanovel Pharmaco-industrial trading companySanovel Pharmaco-industrial trading company Turkey Manufacturer: & nbspSANOVEL PHARMACEUTICAL PRODUCTS IND., Inc. Turkey Representation: & nbspSANOVEL branch of the company pharmaco-industrial trading companySANOVEL branch of the company pharmaco-industrial trading companyRussia Information update date: & nbsp2016-10-24 Illustrated instructions × Illustrated instructions Instructions